What's this project about?
Mutations in the KRAS gene are found in 20 to 25 percent of lung cancers. These cancers do not respond well to standard lung cancer treatments.
Recently there have been important developments in two types of treatment approaches. It’s the job of the Dream Team to find the best way to combine those treatments and create better outcomes for people with the KRAS mutation.
Sign up to get news from the Dream Team as new developments occur in this exciting area of research.
What's the goal of the project?
To develop transformative therapies for people diagnosed with KRAS mutant lung cancer. Read more»
Who are the sponsors?
American Cancer Society
Scientific Oversight and Administration